Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY PanTumor03: Trastuzumab Deruxtecan in HER2-expressing Solid Tumors
NCT06271837Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in solid tumor (4 arms), sponsored by AstraZeneca. Primary endpoint: Confirmed Objective Response Rate at 12 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06271837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271837.